As of Wednesday, Arrowhead Pharmaceuticals Inc.’s (NASDAQ:ARWR) stock closed at $35.99, down from $36.91 the previous day. While Arrowhead Pharmaceuticals Inc. has underperformed by -2.49%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ARWR fell by -37.74%, with highs and lows ranging from $56.47 to $26.81, whereas the simple moving average fell by -2.83% in the last 200 days.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
On September 09, 2022, Morgan Stanley started tracking Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) recommending Equal-Weight. A report published by Robert W. Baird on May 11, 2022, Upgraded its rating to ‘Outperform’ for ARWR. Goldman also rated ARWR shares as ‘Buy’, setting a target price of $85 on the company’s shares in an initiating report dated January 19, 2022. Chardan Capital Markets Reiterated the rating as Buy on August 06, 2021, but set its price target from $97 to $94. Robert W. Baird initiated its ‘Neutral’ rating for ARWR, as published in its report on June 04, 2021. H.C. Wainwright’s report from February 05, 2021 suggests a price prediction of $95 for ARWR shares, giving the stock a ‘Buy’ rating. Robert W. Baird also rated the stock as ‘Neutral’.
Analysis of Arrowhead Pharmaceuticals Inc. (ARWR)
Further, the quarter-over-quarter decrease in sales is -17.50%, showing a negative trend in the upcoming months.
One of the most important indicators of Arrowhead Pharmaceuticals Inc.’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -42.00% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.90, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and ARWR is recording 994.20K average volume. On a monthly basis, the volatility of the stock is set at 6.45%, whereas on a weekly basis, it is put at 6.52%, with a gain of 8.96% over the past seven days. Furthermore, long-term investors anticipate a median target price of $65.38, showing growth from the present price of $35.99, which can serve as yet another indication of whether ARWR is worth investing in or should be passed over.
How Do You Analyze Arrowhead Pharmaceuticals Inc. Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.40%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 68.10% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in ARWR shares?
The recent increase in stakes in ARWR appears to be a result of several institutional investors and hedge funds increasing their positions. BlackRock Fund Advisors’s position in ARWR has decreased by -1.44% in the first quarter. The company now owns 10,963,831 shares of the stock, with a value of $444.69 million, following the sale of -159,683 additional shares during the last quarter. The Vanguard Group, Inc. made another increased to its shares in ARWR during the first quarter, upping its stake by 0.67%. During the last quarter, the company dropped down 65,976 additional shares for a total stake of worth $400.18 million, bringing number of shares owned by the company to 9,866,463.
During the first quarter, SSgA Funds Management, Inc. subtracted a -328,314 position in ARWR. AllianceBernstein LP sold an additional -0.33 million shares in the last quarter, decreasing its holdings by -11.83%, now holding 2.47 million shares worth $100.06 million. At the end of the first quarter, Fidelity Management & Research Co decreased its ARWR holdings by -10.69% and now holds 2.45 million ARWR shares valued at $99.35 million with the lessened -0.29 million shares during the period. ARWR shares are owned by institutional investors to the tune of 68.10% at present.
